



39TH ANNUAL SCIENTIFIC MEETING
OCTOBER 8-12, 2021



ASRS

American Society of
Retina Specialists

FRIDAY, OCTOBER 8

7:00-10:00 PM Welcome Reception

SATURDAY, OCTOBER 9

7:30-8:30 AM Continental Breakfast

8:00-8:05 AM Opening Comments, Judy Kim, MD, FASRS

8:05-9:30 AM Diabetic Retinopathy 1 Symposium8:05 AM Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States, **Rahul Khurana, MD, FASRS**8:11 AM Vitrectomy in Diabetic Macular Edema: A Swept Source OCT Angiography Study, **Zofia A. Nawrocka, MD, PhD, FASRS**8:17 AM Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting, **Matthew Starr, MD**8:23 AM Race Representation in Diabetic Macular Edema Randomized Control Trials Compared to the United States Census Data, **Abdul-Hadi Kaakour, MD, MS**

8:29 AM Discussion

8:41 AM Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR), **W. Lloyd Clark, MD**8:45 AM Early Switch to the Dexamethasone Implant After Sub-Optimal Response to Anti-VEGF Therapy for Diabetic Macular Edema, **Shawn Kavoussi, MD**8:49 AM Amine Oxidase Copper-Containing 3 Inhibitor (BI 1467335) in Non-Proliferative Diabetic Retinopathy: Double-Masked, Randomized, Phase IIa Study (ROBIN), **Quan Nguyen, MD, MSc, FASRS**8:53 AM APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies, **Michael Allingham, MD, PhD**

8:57 AM Discussion

9:05 AM Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials, **Katherine Talcott, MD**9:09 AM Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAC) in Diabetic Macular Edema (DME) Patients, **Victor Gonzalez, MD, FASRS**9:13 AM Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression, **Ehsan Rahimy, MD, FASRS**9:17 AM Impact of Race on Vision Outcomes in Ranibizumab-Treated Patients With Diabetic Macular Edema: A Meta-Analysis of 5 Clinical Trial, **M. Ali Khan, MD, FASRS**

9:21 AM Discussion

9:30-10:10 AM Break

10:10-11:55 AM	Diabetic Retinopathy 2 Symposium
10:10 AM	Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials, Caroline Baumal, MD, FASRS
10:16 AM	Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies, David Brown, MD, FASRS
10:22 AM	Impact of Delayed Treatment in Diabetic Retinal Disease: Experience From VISTA/VIVID and PANORAMA, Sumit Sharma, MD, FASRS
10:28 AM	Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial, Charles Wykoff, MD, PhD, FASRS
10:34 AM	Discussion
10:46 AM	Aflibercept Versus Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy, Hani Salehi-Had, MD
10:52 AM	A Randomized Trial of Intravitreal Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W), Raj Maturi, MD, FASRS
10:58 AM	What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials, Sophie Bakri, MD, FASRS
11:04 AM	Diabetic Retinopathy Telemedicine Outcomes With Artificial Intelligence-Based Image Analysis, Reflex Dilation, and Image Overread Protocol, Andrew Barkmeier, MD, FASRS
11:10 AM	Qualitative and Quantitative Evaluation of Diabetic Choroidopathy Using Ultra-Widefield Indocyanine Green Angiography (UWF ICGA), Young Hee Yoon, MD, PhD
11:16 AM	Discussion
11:31 AM	Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE Study, Dennis Marcus, MD, FASRS
11:35 AM	Comparing Rates of Vitrectomy in Proliferative Diabetic Retinopathy Patients Treated With Anti-VEGF or Panretinal Photocoagulation Monotherapy, Nadim Rayess, MD
11:39 AM	Steroid vs. Anti-VEGF for Diabetic Macular Edema Prior to Phacoemulsification (STAMP), Caesar Luo, MD, FASRS
11:43 AM	Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID, Rishi Singh, MD, FASRS
11:47 AM	Discussion

11:55 AM-1:10 PM General Lunch & Fellowship Directors' Section Lunch

1:10-1:50 PM	Pharmacology Symposium
1:10 PM	Evaluating Pentosan Polysulfate Sodium-Associated Retinopathy Risk Factors and Grading Criteria, S. Krishna Mukkamala, MD
1:16 PM	Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes, James Major, MD, PhD, FACS, FASRS
1:22 PM	Discussion

1:31 PM	Comparison of Hypochlorous Acid vs. Povidone Iodine Use Prior to Intravitreal Injection: A Randomized Prospective Trial (PAVE Study), Robert Avery, MD, FASRS
1:35 PM	Pentosan Polysulfate Maculopathy: Prospective Observational Study, Nieraj Jain, MD, FASRS
1:39 PM	Efficacy and Safety of 'Dropless Vitrectomy Surgery' and Comparison of Outcomes to Standard of Care Topical Therapy, K. Chalam, MD, PhD, MBA, FRCS(C), FASRS
1:43 PM	Discussion

1:50-2:35 PM Pediatric Retina - ROP Symposium

1:50 PM	Computerized Analysis of Retinal Vascular Growth Following Intravitreal Bevacizumab Monotherapy in Retinopathy of Prematurity Until Three Years of Age, Swati Agarwal-Sinha, MD, FASRS
1:56 PM	Ophthalmic Manifestations Associated With SARS-CoV-2 in Newborn Infants: A Preliminary Report, Maria Martinez-Castellanos, MD
2:02 PM	Discussion
2:11 PM	Giant Retinal Tear Detachments in LEPREL1 Mutations Mimicking Ocular Stickler Syndrome: A Condition With an Associated Nephropathy, Sulaiman Al Sulaiman, MD
2:15 PM	Evaluation of Nationwide Trends in Retinopathy of Prematurity Care, Adrienne Scott, MD, FASRS
2:19 PM	Vitreoretinal Interface in Pediatric Retinal Detachment, Carl Claes, MD
2:23 PM	Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy, Lucy Xu, MD
2:27 PM	Discussion

2:35-3:15 PM Break

3:15-4:25 PM Inflammatory & Infectious Diseases Symposium

3:15 PM	Outcomes of Rhegmatogenous Retinal Detachment Repair Following Infectious Endophthalmitis, Frances Wu, MD
3:21 PM	Bacterial Dispersion Associated With Various Patient Face Mask Designs During Simulated Intravitreal Injections, Samir Patel, MD
3:27 PM	Investigation of Microbial Content of Face Masks Used by Patients Receiving Intravitreal Injections, Avinash Honasoge, MD, PhD
3:33 PM	A 10-Year Follow-up on Outcomes of Intravitreal Anti-VEGF Injections for Choroidal Neovascularization Secondary to Ocular Histoplasmosis, Carl Noble, DO, MBA
3:39 PM	Prospective Use of Imaging Quantification of Inflammation: Determining Uveitis Activity and Correlating to Visual Acuity, Jordan Deaner, MD
3:45 PM	Discussion
4:00 PM	Evaluation of Prevalence and Risk for Vitreoretinal Involvement in Fungemic Patients at a Tertiary Care Hospital, Carl Wilkins, MD
4:04 PM	Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema, Dilraj Grewal, MD, FASRS

4:08 PM	Acute Retinal Necrosis: Clinical Characteristics, Viral Etiology, and Risk Factors Associated With Retinal Detachment, James Bavinger, MD
4:12 PM	Post Hoc Analysis of Suprachoroidal CLS-TA Versus Real-World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function, Steven Yeh, MD, FASRS
4:16 PM	Discussion
<hr/>	
4:25-5:35 PM	2020 Awards Ceremony
4:25 PM	Pyron Award Introduction
4:27 PM	Pyron Award, Advanced Retinal Implants, Mark S. Humayun, MD, PhD
4:40 PM	Founders Award Introduction
4:42 PM	Founders Award, Carl D. Regillo, MD, FASRS
4:55 PM	Early Career Section (ECS) Crystal Apple Awards Presentation to Caroline Baumal, MD, FASRS
5:00 PM	ASRS Presidents' Retina Young Investigators Award Introduction, Timothy G. Murray, MD, MBA, FASRS
5:02 PM	ASRS Presidents' Retina Young Investigators Award, Charles C. Wykoff, MD, PhD, FASRS
5:10 PM	Packo Award Presentation to Jerald A. Bovino, MD, FASRS, Roy A. Levit, MD, FASRS, and Allen Z. Verne, MD, FASRS
5:20 PM	Retina Hall of Fame Award
<hr/>	
5:35-6:35 PM	Scientific Poster Q&A and Exhibit Hall Reception
<hr/>	
6:35-7:35 PM	FIT & Resident Reception

SUNDAY, OCTOBER 10

7:30-8:30 AM Continental Breakfast

8:00-8:05 AM Opening Remarks, Carl Awh, MD, FASRS

8:05-8:40 AM Complications of Anterior Segment Surgery Symposium

- 8:05 AM Different Methods in Secondary Intraocular Lens Implantation, **Stanislao Rizzo, MD, FASRS**
- 8:11 AM A Technique for Sutured Scleral Fixation of One-Piece Hydrophobic Acrylic and Hydrophilic Acrylic Intraocular Lenses Dislocated Into the Vitreous, **Marcin Czajka, MD, PhD**
- 8:15 AM Comparison of 25- and 27-Gauge Sutureless Cannula-Based Intraocular Lens Scleral Fixation Visual Acuity Outcomes and Complication Rates, **Ankoor Shah, MD, FASRS**
- 8:19 AM Endophthalmitis Following Minimally Invasive Glaucoma Surgery: Incidence, Clinical Features, Microbiology, and Management Outcomes, **Yoshihiro Yonekawa, MD, FASRS**
- 8:23 AM Scleral-Sutured Intraocular Lens Dislocations Secondary to Eyelet Fractures, **Nimesh Patel, MD**
- 8:27 AM Discussion
-

8:40-9:35 AM Socioeconomic/Practice Management Symposium

- 8:40 AM DME project paper (title TBA)
- 8:46 AM Are Graduating Vitreoretinal Surgeons Avoiding Private Equity Jobs?, **Naryan Sabherwal, MD**
- 8:52 AM Representation of Women in Vitreoretinal Meeting Faculty Roles From 2015 Through 2019, **Jayanth Sridhar, MD, FASRS**
- 8:58 AM Discussion
- 9:08 AM Trends in Medicare Reimbursement for Common Vitreoretinal Procedures: 2011-2020, **Shriji Patel, MD, FASRS**
- 9:14 AM Board-Certified Providers Are Associated With a Reduced Risk of Endophthalmitis After Intravitreal Injections, **Geoffrey Emerson, MD, PhD, FASRS**
- 9:20 AM The Conundrum of Intravitreal Injections and Use of -25 Modifier for Same-Day Office Visits, **John Thompson, MD, FASRS**
- 9:26 AM Discussion
-

9:35-10:10 AM COVID Symposium

- 9:35 AM The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During the COVID-19 Pandemic, **Sunir Garg, MD, FACS, FASRS**
- 9:41 AM Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits, **William Smiddy, MD**
- 9:45 AM Results of One Year of Contact Precautions During COVID-19: Universal Gloving, Masking of Patients and Double Masking of Staff in a Retina Practice, **Abdhis Bhavsar, MD, FASRS**

9:49 AM	The Impact of COVID-19 on US and International Retina Specialists, Their Practices, and Their Patients, Paul Hahn, MD, PhD, FASRS
9:53 AM	Quality of Life and Retinal Disease During the COVID-19 Pandemic, Peter Zhao, MD
9:57 AM	Discussion
10:10-10:50 AM	Break
10:50-10:55 AM	Retina PractiCare 2.0, John Thompson, MD, FASRS
10:55-11:10 AM	Health Policy Panel
11:10-12:10 PM	2021 Awards Ceremony
11:10 AM	Pyron Award Introduction
11:12 AM	Pyron Award, Cynthia A. Toth, MD
11:25 AM	Founders Award Introduction
11:27 AM	Founders Award, Stanislao Rizzo, MD, FASRS
11:40 AM	Early Career Section (ECS), Crystal Apple Award Presentation to R.V. Paul Chan, MD
11:45 AM	ASRS Presidents' Retina Young Investigators Award Introduction, Timothy G. Murray, MD, MBA, FASRS
11:47 AM	ASRS Presidents' Retina Young Investigators Award, Arshad M. Khanani, MD, MA, FASRS
11:55 AM	Packo Award Presentation to Reginald J. Sanders, MD
12:05 PM	Retina Image Bank, Image of the Year Award, Suber Huang, MD, MBA, FASRS
12:10-1:25 PM	General Lunch & Early Career Section Lunch
1:25-1:35 PM	Business Meeting—Members Only
1:35-1:50 PM	PAT Survey & Global Trends
1:50-3:05 PM	Surgical Techniques & Maneuvers Symposium
1:50 PM	A Randomized Clinical Trial of Pneumatic Vitreolysis for Vitreomacular Traction: DRCR Retina Network Protocol AG, Clement Chan, MD, FACS
1:56 PM	A Single-Arm Study of Pneumatic Vitreolysis for Macular Hole: DRCR Retina Network Protocol AH, Calvin Mein, MD, FASRS
2:02 PM	Discussion
2:07 PM	Carlevalle IOL: The Ultimate Scleral Fixated IOL, Stratos Gotzaridis, MBBS, MD
2:13 PM	Cystoid Macular Edema After Scleral-Fixation of the Akreos AO60 Intraocular Lens, Sneha Padidam, MD
2:19 PM	Wavefront Aberrometry in Pseudophakic Patients Before and After Vitrectomy for Bothersome Floaters, Daniel Adelberg, MD, FASRS
2:25 PM	Discussion
2:34 PM	Visual Recovery and Complication Rates in Anterior Chamber Intraocular Lens Implantation Patients, Uday Desai, MD, FASRS
2:38 PM	A Titanium Macular Buckle Implant Designed for an Easy Placement in Myopic Macular Holes, Levent Akduman, MD

2:42 PM	Small Gauge Pars Plana Vitrectomy for Visually Significant Vitreous Floaters, Matthew Cunningham, MD
2:46 PM	Limited Vitrectomy Improves Contrast Sensitivity Function in Eyes With Multi-Focal IOLs, J. Sebag, MD, FACS, FRCOphth, FARVO
2:50 PM	Outcomes of the “Modified” Yamane Technique: 25-Gauge Trocar Assisted Flanged Intraocular Lens Fixation, Warren Sobol, MD
2:54 PM	Discussion

3:05-3:45 PM Break

3:45-5:15 PM Imaging, Digital, Angiography Symposium

3:45 PM	The Impact of Image Processing Algorithms on Quantitative Optical Coherence Tomography Angiography Metrics in Diabetic Retinopathy, Jay Wang, MD
3:51 PM	Evaluation of Nonperfusion Area and Other Vascular Metrics by Widefield SS-OCTA as Biomarkers of Diabetic Retinopathy Severity, John Miller, MD
3:57 PM	Unsupervised Deep Learning for Grading Age-Related Macular Degeneration Using Retinal Fundus Images, Neesurg Mehta, MD
4:03 PM	Discussion
4:12 PM	Evaluation of Real-Time Volumetric (4D) and B-Scan Images Acquired With Microscope Integrated OCT on a 3D Platform During Human Vitreoretinal Surgery, Henry Feng, MD
4:18 PM	Commercial OCT Enters the Cellular Age – Tracking Macrophage Surveillance of the Macula Circulation!, Richard Rosen, MD, DSc(Hon), FASRS
4:24 PM	Annular Array Ultrasound: New Dimensions and Clinical Capability (Commercial Devices), Yale Fisher, MD
4:30 PM	Discussion
4:39 PM	Characterization and Diagnosis of Retinoschisis and Schisis Detachments Using Spectral Domain Optical Coherence Tomography, Rohan Jalalizadeh, MD
4:43 PM	Feasibility and Clinical Utility of Ultra-Widefield Navigated Swept-Source Optical Coherence Tomography Imaging, Kyle Kovacs, MD
4:47 PM	One-Year Outcome and Predictors of Treatment Outcome in Central Serous Chorioretinopathy: Multimodal Imaging Based Analysis, Supriya Arora, MS
4:51 PM	Discussion
4:57 PM	Hybrid Telemedicine for Retina During COVID-19 and Beyond: Initial Experience With 500+ Patients, Samuel Houston, MD, FASRS
5:01 PM	OCT-A Findings in Pediatric Retina, Audina Berrocal, MD, FASRS
5:05 PM	Recognizable Patterns of Submacular Fibrosis in the Enhanced S-Cone Syndrome, Sawsan Nowilat, MD, FASRS
5:09 PM	Discussion

5:15-6:45 PM WinR Case Conference

MONDAY, OCTOBER 11**7:30-8:30 AM Continental Breakfast****8:00-9:30 AM Wet AMD 1 Symposium**

- 8:00 AM Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS), **Chirag Jhaveri, MD, FASRS**
- 8:06 AM Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD, **Arshad Khanani, MD, MA, FASRS**
- 8:10 AM Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials, **Karl Csaky, MD, PhD**
- 8:16 AM Prospective Longitudinal Study: Fluid Quantification From Daily Self-imaging With Home OCT in Neovascular Age-Related Macular Degeneration (NV-AMD), **Jeffrey Heier, MD, FASRS**
- 8:22 AM Discussion
- 8:32 AM Real-World Scenarios in Surgical Management of Submacular Haemorrhages, **Subhendu Kumar Boral, MBBS, MD(AIIMS), DNB(OPHTHALMOLOGY), FASRS**
- 8:38 AM Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results, **Lejla Vajzovic, MD, FASRS**
- 8:44 AM Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study, **Mark Barakat, MD, FASRS**
- 8:50 AM Intravitreal Gene Therapy for Neovascular AMD with ADVN-022: Results of the Phase 1 OPTIC Trial, **Dante Pieramici, MD, FASRS**
- 8:56 AM Discussion
- 9:07 AM Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER, **David Eichenbaum, MD, FASRS**
- 9:11 AM Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments, **Rehan Hussain, MD**
- 9:15 AM Key Pearls of Conjunctival and Tenon's Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS), **Veeral Sheth, MD, MBA, FASRS**
- 9:19 AM Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS), **Jordan Graff, MD**
- 9:23 AM Discussion

9:30-10:10 AM Break**10:10-11:05 AM Dry AMD Symposium**

- 10:10 AM Machine Learning Enabled Outer Retinal OCT Biomarker Extraction for Identification of High-Risk AMD Eyes for Subfoveal Geographic Atrophy Progression, **Kubra Sarici, MD**

- 10:16 AM Clinical and Demographic Factors Associated With Loss to Follow-up in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, **Durga Borkar, MD**
- 10:22 AM Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial, **Jason Hsu, MD**
- 10:28 AM Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics, **David Lally, MD, FASRS**
- 10:34 AM Discussion
- 10:46 AM Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy, **Peter Kaiser, MD, FASRS**
- 10:50 AM Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study, **Nancy Holekamp, MD, FASRS**
- 10:54 AM Visual Acuity and Reading With One Eye Versus Both Eyes Open in Geographic Atrophy and Associations With Patient-Reported Vision-Related Function, **Jun Kong, MD, PhD**
- 10:58 AM Discussion

11:05 AM-12:25 PM Wet AMD 2 Symposium

- 11:05 AM Cognitive Testing in Patients Receiving Intravitreal Anti-VEGF Injections for Neovascular Age-Related Macular Degeneration (Update on the BHAM Study), **Subhransu Ray, MD, PhD, FASRS**
- 11:11 AM Factors Affecting Disease Activity in Neovascular Age-Related Macular Degeneration, **Colin Tan, MBBS, MMed (Ophth), FRCSEd (Ophth), FASRS**
- 11:17 AM Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD, **Carl Awh, MD, FASRS**
- 11:23 AM Discussion
- 11:32 AM Long-term Experience With Intravitreal Anti-VEGF Treatment in Patients With nAMD: Analysis of IRIS® (Intelligent Research in Sight) Registry Database, **Theodore Leng, MD, MS**
- 11:38 AM Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States, **Rebecca Soares, MD**
- 11:44 AM Apples and Oranges: “Real-World” Outcomes Differ From Clinical Trial Outcomes Because “Real-World” Patients Differ From Clinical Trial Patients, **Franco Recchia, MD**
- 11:50 AM Discussion
- 11:59 AM Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial, **John Kitchens, MD, FASRS**
- 12:03 PM Treatment Patterns and Visual and Health Function in Neovascular Age-Related Macular Degeneration (nAMD): Medicare Current Beneficiary Survey Analysis, **Ferhina Ali, MD, MPH**
- 12:07 PM Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy, **Scott Walter, MD, MSc**

12:11 PM	Severe Visual Loss During Anti-VEGF Therapy for Wet Age-Related Macular Degeneration: OCT Correlation and Functional Prognosis, Francesco Boscia, MD
12:15 PM	Discussion
<hr/>	
12:25-1:40 PM	General Lunch & WinR/Diversity & Inclusion Lunch
<hr/>	
1:40-2:45 PM	Macular Surgery Symposium
1:40 PM	Feasibility and Validation of a Deep-Learning Algorithm for the Detection of Macular Holes With Spectral Domain Optical Coherence Tomography, Jessica Cao, MD
1:46 PM	Combined Epiretinal Membrane and Internal Limiting Membrane Flaps for Macular Holes Associated With Epiretinal Membranes, Elizabeth Marlow, MD
1:52 PM	Large Operative Case Series of Degenerative Lamellar Macular Holes, Chirag Shah, MD, MPH, FASRS
1:58 PM	The Proteome of Preretinal Tissue in Proliferative Vitreoretinopathy and Epiretinal Membrane: Differential Expression of Extracellular Matrix, Charles Miller, MD, PhD
2:04 PM	Fovea-Sparing Versus Standard Internal Limiting Membrane Peeling for Myopic Traction Maculopathy, Taku Wakabayashi, MD
2:10 PM	Discussion
2:26 PM	Superior Wide-Base Internal Limiting Membrane Flap Transposition (SWIFT) for Macular Holes, Homayoun Tabandeh, MD, FASRS
2:30 PM	ILM Peel, Retinal Hydration, Fibrin Glue, and C3F8 Gas for Recalcitrant Macular Holes, Kamal Kishore, MD, MBBS, FASRS
2:34 PM	The Role of Face Down Positioning in the Successful Repair of Full Thickness Macula Holes, Keith Warren, MD
2:38 PM	Discussion
<hr/>	
2:45-3:25 PM	Break
<hr/>	
3:25-3:55 PM	Ocular Oncology Symposium
3:25 PM	A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma, Prithvi Mruthyunjaya, MD, MHS, FASRS
3:31 PM	Clinical Spectrum of Uveal Metastasis in Korean Patients Based on Primary Tumor Origin, Min Kim, MD, FASRS
3:37 PM	Comparison of Tumor Size at Presentation and Genomics in Uveal Melanoma Patients Before and After the COVID-19 Pandemic, Amy Scheffler, MD, FACS, FASRS
3:41 PM	Combined MIVS/Phacoemulsification for Concomitant Management of Retinal Pathology With Cataract: 5-Year Follow-up of a Large, Consecutive Case Series, Timothy Murray, MD, MBA, FASRS
3:45 PM	Discussion

3:55-4:25 PM	Instrumentation & Devices Symposium
3:55 PM	Feasibility and Utility of Microscope-Integrated Intraoperative OCT for Vitreoretinal Surgery: The DISCOVER Study 7-Year Results, Danny Mammo, MD
4:01 PM	Comparison of Suprachoroidal and Intravitreal Injection Flow Mechanics Analyzed via Multimodal Imaging, Shree Kurup, MD
4:07 PM	A Comparison of Superficial Macular Anatomic Changes Following ILM peeling Using a Micro-Vacuum Pick (MVP) Versus Forceps, Akshay Thomas, MD, MS
4:11 PM	Quality Assessment of a New Silicone-Free Syringe Developed for Intravitreal Injections, Gustavo Melo, MD, PhD, FASRS
4:15 PM	Discussion

4:25-4:45 PM	AMD Panel
---------------------	------------------

7:00-10:00 PM	Gala Dinner
----------------------	--------------------

TUESDAY, OCTOBER 12

7:30-8:30 AM Continental Breakfast

8:00-9:30 AM Retinal Detachment Symposium

- 8:00 AM Real-Time In Vivo Assessment of Retinal Reattachment in Humans Using Swept-Source Optical Coherence Tomography, **Rajeev Muni, MD, MSC, FRCS(C), FASRS**
- 8:06 AM Postoperative Outer Retinal Folds in Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment: PIVOT Post Hoc Analysis, **Wei Wei Lee, MD**
- 8:12 AM Opportunity Cost of Retinal Detachment Surgery Versus Office-Based Patient Care, **Ella Leung, MD**
- 8:18 AM Discussion
- 8:27 AM Postoperative Intravitreal Methotrexate Injections Reduce Reoperations in Eyes With Proliferative Vitreoretinopathy and Diabetic Retinopathy, **Alan Franklin, MD, PhD**
- 8:33 AM Retinal Displacement After Pneumatic Retinopexy vs Vitrectomy for Rhegmatogenous Retinal Detachment (ALIGN STUDY), **Carolina Francisconi, MD**
- 8:39 AM Rho-kinase Inhibition on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy, **Leo Kim, MD, PhD, FASRS**
- 8:45 AM Discussion
- 8:54 AM Contemporary Management of Complex and Non-complex Rhegmatogenous Retinal Detachment Due to Giant Retinal Tears, **Thomas Wubben, MD, PhD**
- 8:58 AM Real-World Trends in Surgical Care for Retinal Detachment Repair Among Vitreoretinal Surgeons in the United States, **Avni Finn, MD, MBA**
- 9:02 AM Outcomes of Intravitreal Methotrexate for Proliferative Vitreoretinopathy in the Perioperative Period of Retinal Detachment Repair, **Michelle Abou-Jaoude, MD**
- 9:06 AM Discussion
- 9:12 AM Smoking and Increased Risk of PVR: Is Increased TNF- α a Key Causative Factor?, **Ajay Kuriyan, MD, MS, FASRS**
- 9:16 AM Impact of the COVID-19 Pandemic on Characteristics of Retinal Detachments: The Canadian Experience, **Parnian Arjmand, MD, MSc, FRCSC**
- 9:20 AM Surgical Outcomes in Patients With Retinal Detachment Treated With a Novel Heavy Silicone Oil, **Rajinder Nirwan, MD, FRCSC, DABO**
- 9:24 AM Discussion

9:30-10:10 AM Break

10:10-11:15 AM Retinal Vascular Disease Symposium

- 10:10 AM Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion, **Carl Danzig, MD, FASRS**
- 10:16 AM Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion, **Glenn Yiu, MD, PhD, FASRS**
- 10:22 AM Phase 2 Study of Two Formulations of AR-1105 in Macular Edema (ME) Secondary to Retinal Vein Occlusion (RVO), **Michael Singer, MD, FASRS**

10:28 AM	Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO, Suber Huang, MD, MBA, FASRS
10:34 AM	Analysis of Efficacy of Thrombophilia Workup in Retinal Vein Occlusion Patients, Katrina Mears, MD, MSc, FACS, FASRS
10:40 AM	Discussion
10:57 AM	Treatment of Central Retinal Artery Occlusion With Intra-arterial Tpa, Gareth Lema, MD, PhD
11:01 AM	Intravitreal Anti-VEGF Therapy in Maintaining Long-term Driving Vision in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration, Parisa Emami Naeini, MD, MPH
11:05 AM	Office Based Flicker ERG for Monitoring the Course of CRVO and HRVO Treated With Intravitreal Anti-VEGF and Suprachoroidal Triamcinolone Therapy, John Wroblewski, MD
11:09 AM	Discussion
<hr/>	
11:15-11:35 AM	Late-breaking Abstracts
<hr/>	
11:35-11:40 AM	Closing Remarks, Judy Kim, MD, FASRS

The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this Other activity (blended live and enduring material) for a maximum of 22.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the ACCME's Standards for Commercial Support, ASRS required all individuals controlling the content of this CME activity to disclose all financial relationships with any ineligible companies. ASRS implemented mechanisms to mitigate those relevant financial relationships to prevent commercial bias. Please see the program booklet (our mobile meeting site) for disclosure information for all planners and teachers of this CME activity.

